Name: Rigel Pharmaceuticals, Inc. (RIGL) Financial Statements
Creator: FinSpry

Rigel Pharmaceuticals Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Rigel Pharmaceuticals, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
Revenue & Gross Profit
Revenue	179.28	116.88	120.24	138.74	108.62	59.29	44.51
Cost of Revenue	18.65	7.11	1.75	66.32	0.90	0.91	0.29
Gross Profit	160.63	109.77	118.49	72.42	107.73	58.38	44.22
Operating Expenses
Research & Development	23.38	24.52	60.27	65.24	60.10	52.89	46.90
Selling, General & Administrative	113.06	105.74	112.45	91.89	76.60	74.59	70.00
Operating Expenses	136.44	130.26	172.72	91.89	136.70	127.47	116.91
Operating Income	24.19	-20.49	-55.55	-19.48	-28.97	-69.09	-72.68
Other Income/Expense
Interest Income	2.09	2.27	0.68	0.05	0.58	0.00	2.20
Interest Expense	7.92	6.87	-3.71	-4.86	-1.35	0.00	0.00
Other Income/Expense	-5.83	0.70	-1.32	-3.52	-0.09	-0.50	0.00
Income
Income Before Tax	18.37	-25.09	-58.57	-17.31	-29.74	-66.89	-70.48
Income Tax Expense	0.88	0.00	0.00	0.61	0.00	0.00	0.00
Net Income	17.49	-25.09	-58.57	-17.91	-29.74	-66.89	-70.48
Net Income - Continuous Operations	17.49	-25.09	-58.57	-17.91	0.00	0.00	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	28.51	-16.98	-53.87	-18.31	-27.69	-65.88	-69.89
EBIT	26.28	-18.22	-54.87	-19.48	-28.39	-66.56	-70.48
Depreciation & Amortization	2.23	1.24	1.00	1.16	0.71	0.68	0.00
Earnings Per Share
Basic EPS	1.00	-1.00	-	-1.00	-	-	-
Diluted EPS	1.00	-1.00	-	-1.00	-	-	-
Basic Shares Outstanding	17.58	17.40	172.41	17.05	168.75	167.40	160.53
Diluted Shares Outstanding	17.69	17.40	172.41	17.05	16.88	167.40	160.53